Update shared on 10 Dec 2025
Fair value Decreased 4.30%Analysts have trimmed their price target on agilon health by roughly 4 percent to reflect slightly softer expectations for revenue growth, profitability, and future valuation multiples while maintaining a largely similar risk profile.
What's in the News
- New York Stock Exchange notified agilon health that its shares no longer meet the minimum 1 dollar average closing price requirement over a 30 day trading period, which triggered a cure period while the stock remains listed and traded on the NYSE (Key Developments).
- The company plans to pursue a reverse stock split, subject to shareholder approval at the 2026 annual general meeting, as a key step to regain compliance with NYSE listing standards (Key Developments).
- agilon health re established earnings guidance for fiscal 2025, projecting total revenues between 5,810 million dollars and 5,830 million dollars for the year (Key Developments).
Valuation Changes
- Fair Value Estimate decreased slightly from 1.01x to 0.97x, reflecting a modestly lower implied intrinsic value multiple.
- Discount Rate remained effectively unchanged at approximately 6.96 percent, indicating a stable perceived risk profile.
- Revenue Growth Assumption was reduced modestly from about 7.25 percent to 7.00 percent, signaling slightly more conservative top line expectations.
- Net Profit Margin was trimmed marginally from roughly 5.48 percent to 5.45 percent, implying a small reduction in long term profitability assumptions.
- Future P/E was lowered slightly from about 1.31x to 1.26x, pointing to a modest compression in forward valuation multiples.
Have other thoughts on agilon health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.